Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MMP15 | P51511 | 1/20 | 0.36 |
| ▸ | MMP16 | P51512 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435377 | 0.90 | NPSR1 (0.51) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL1039792 | 0.88 | LMNA (0.51) | NPSR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL5506728 | 0.88 | LMNA (0.51) | NPSR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL1035128 | 0.85 | TSHR (0.48) | POLBNPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL1038263 | 0.84 | LMNA (0.40) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL1040056 | 0.83 | MMP1 (0.41) | ESR1NPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL9684628 | 0.79 | MCOLN3 (0.50) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL9685672 | 0.79 | MCOLN3 (0.50) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL2389980 | 0.79 | MCOLN3 (0.50) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL9380136 | 0.79 | MCOLN3 (0.50) | POLBMCOLN3L3MBTL1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1897879-A2 | 2,4,5 substituted piperidines as renin inhibitors | Speedel Experimenta AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | ESR1 3067/4885POLB 2005/4885MCOLN3 4835/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | ESR1 2613/4885POLB 2217/4885MCOLN3 4449/4885 |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | ESR1 3586/4885POLB 1015/4885MCOLN3 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.